4.5 Article

Subclinical Inflammation with Increased Neutrophil Activity in Healthy Twin Siblings Reflect Environmental Influence in the Pathogenesis of Inflammatory Bowel Disease

期刊

INFLAMMATORY BOWEL DISEASES
卷 19, 期 8, 页码 1725-1731

出版社

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0b013e318281f2d3

关键词

inflammatory bowel disease; twins; genetics; subclinical activity; nuclear factor-kappa B; myeloperoxidase; F-calprotectin

资金

  1. Bengt Ihre's foundation
  2. Nanna Svartz' foundation
  3. Orebro University Hospital Research Foundation
  4. Orebro County Research Foundation
  5. Swedish Foundation for Gastrointestinal research
  6. Swedish Research Council

向作者/读者索取更多资源

Background:The mechanisms behind increased fecal calprotectin (FC) in healthy relatives of patients with inflammatory bowel disease (IBD) are unknown. Our aims were to explore if there is a subclinical inflammation with increased neutrophil activity in healthy twin siblings in discordant twin pairs with IBD and to assess the influence of genetics in this context.Methods:Nuclear factor kappa B (NF-B) and neutrophil activity, based on myeloperoxidase (MPO) and FC, were analyzed in healthy twin siblings in discordant twin pairs with IBD and compared with healthy controls. NF-B and MPO were assessed by immunohistochemistry and FC by enzyme-linked immunosorbent assay.Results:In total, 33 of 34 healthy twin siblings were histologically normal. Increased NF-B was more often observed in healthy twin siblings in discordant twin pairs with Crohn's disease (13/18 [73%]) and with ulcerative colitis (12/16 [75%]) than in healthy controls (8/45 [18%]). MPO was more often increased in healthy twin siblings in discordant pairs with Crohn's disease (12/18 [67%]) than in healthy controls (11/45 [24%]) and FC more often in healthy twin siblings in discordant pairs with ulcerative colitis (14/21 [67%]) than in healthy controls (6/31 [19%]). Interestingly, the observed differences remained when healthy monozygotic and dizygotic twin siblings were analyzed separately.Conclusions:We observed increased NF-B, MPO, and FC in healthy twins in both monozygotic and dizygotic discordant pairs with IBD. These novel findings speak for an ongoing subclinical inflammation with increased neutrophil activity in healthy first-degree relatives.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease

Anders Forss, Mark Clements, Par Myrelid, Hans Strid, Charlotte Soderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson

Summary: This study demonstrates the long-term clinical effectiveness of ustekinumab in patients with active Crohn's disease, as well as its improvement in Health-related Quality of Life (HRQoL) measures.

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Gastroenterology & Hepatology

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

Johanna Holmgren, Anna Froborg, Isabella Visuri, Jonas Halfvarson, Henrik Hjortswang, Pontus Karling, Par Myrelid, Ola Olen, Jonas F. Ludvigsson, Olof Grip

Summary: In patients with inflammatory bowel disease, the incidence rate of serious infection did not increase with the use of anti-TNF therapy and actually decreased more than 1 year after treatment initiation.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie

Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Bidirectional Mendelian Randomisation Analysis Provides Evidence for the Causal Involvement of Dysregulation of CXCL9, CCL11 and CASP8 in the Pathogenesis of Ulcerative Colitis

Jie Chen, Yajing Zhou, Yuhao Sun, Shuai Yuan, Rahul Kalla, Jing Sun, Jianhui Zhao, Lijuan Wang, Xuejie Chen, Xuan Zhou, Siqi Dai, Yu Zhang, Gwo-tzer Ho, Dajing Xia, Qian Cao, Zhanju Liu, Susanna C. Larsson, Xiaoyan Wang, Kefeng Ding, Jonas Halfvarson, Xue Li, Evropi Theodoratou, Jack Satsangi

Summary: This study identified 14 proteins associated with the risk of ulcerative colitis (UC) through the analysis of serum proteomic profiling data. Further analysis using Mendelian randomisation confirmed the causal relationship between two chemokines and the increased risk of UC. Additionally, a new protein associated with UC risk was identified. Reverse Mendelian randomisation analysis did not find any influence of genetic predisposition to UC on these three inflammation proteins.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A. Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig

Summary: This study aimed to compare the relapse rate and time in remission over 2 years between patients continuing combination therapy, stopping infliximab, or stopping immunosuppressant therapy for Crohn's disease. The results showed that stopping infliximab had a higher relapse rate compared to stopping immunosuppressant therapy, suggesting that stopping immunosuppressant therapy may be a preferable strategy for treatment de-escalation.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Genetics & Heredity

Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries

Zhanju Liu, Ruize Liu, Han Gao, Seulgi Jung, Xiang Gao, Ruicong Sun, Xiaoming Liu, Yongjae Kim, Ho-Su Lee, Yosuke Kawai, Masao Nagasaki, Junji Umeno, Katsushi Tokunaga, Yoshitaka Kinouchi, Atsushi Masamune, Wenzhao Shi, Chengguo Shen, Zhenglin Guo, Kai Yuan, Shu Zhu, Dalin Li, Jianjun Liu, Tian Ge, Judy Cho, Mark J. Daly, Dermot P. B. McGovern, Byong Duk Ye, Kyuyoung Song, Yoichi Kakuta, Mingsong Li, Hailiang Huang, Maria Abreu, Jean-Paul Achkar, Vibeke Andersen, Charles Bernstein, Steven R. Brant, Luis Bujanda, Siew Chien Ng, Judy Cho, Mark J. Daly, Lee A. Denson, Richard H. Duerr, Lynnette R. Ferguson, Denis Franchimont, Andre Franke, Richard Gearry, Hakon Hakonarson, Jonas Halfvarson, Caren Heller, Hailiang Huang, Antonio Julia, Judith Kelsen, Hamed Khalili, Subramaniam Kugathasan, Juozas Kupcinskas, Anna Latiano, Edouard Louis, Reza Malekzadeh, Jacob L. McCauley, Dermot P. B. McGovern, Christopher Moran, David Okou, Tim Orchard, Aarno Palotie, Miles Parkes, Joel Pekow, Uros Potocnik, Graham Radford-Smith, John D. Rioux, Gerhard Rogler, Bruce Sands, Mark Silverberg, Harry Sokol, Severine Vermeire, Rinse K. Weersma, Ramnik J. Xavier, Naizhong Hu, Qian Cao, Yufang Wang, Yinglei Miao, Hongjie Zhang, Xiaoping Lv, Xiang Gao, Hu Zhang, Jingling Su, Baisui Feng, Ye Zhao, Liangru Zhu, Yan Chen, Lanxiang Zhu, Chunxiao Chen, Yali Wang, Yingde Wang, Zhi Pang, Yingxuan Chen, Xiaolan Zhang, Hui Li, Qin Yu, Mei Ye, Sumin Zhang, Wen Tang, Mei Wang, Xiaocang Cao, Ruixin Zhu, Guangxi Zhou, Zhaolian Bian, Xiaofeng Guo, Xiaoli Wu, Jinchun Liu, Wei Xu, Yuqin Li, Qin Guo, Zhiguo Guo, Mingsong Li, Zhanju Liu

Summary: This study provides the largest investigation of inflammatory bowel diseases (IBDs) in individuals of East Asian ancestries, identifying 80 IBD loci, including 81 new loci. The study also discovers new IBD genes, such as ADAP1 and GIT2, and improves the accuracy of predicting IBD risk by incorporating data from both East Asian and European ancestries.

NATURE GENETICS (2023)

Article Medicine, General & Internal

Long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa: A population-based, sibling-controlled cohort study in Sweden

Jiangwei Sun, Fang Fang, Ola Olen, Mingyang F. Song, Jonas Halfvarson, Bjorn Roelstraete, Hamed Khalili, Jonas Ludvigsson

Summary: In this study, individuals who underwent endoscopic biopsy with normal mucosa were followed up for a median of 10 years. The study found that these individuals had an elevated risk of inflammatory bowel disease (IBD) for at least 30 years. These findings imply the presence of a substantial symptomatic period before the diagnosis of IBD and emphasize the importance of considering the long-term risk of IBD in patients with symptoms but normal mucosa on gastrointestinal investigation.

PLOS MEDICINE (2023)

Article Gastroenterology & Hepatology

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis

Aiva Lundberg Bave, Ola Olen, Jonas Soederling, Jonas F. Ludvigsson, Annika Bergquist, Caroline Nordenvall

Summary: Colectomy in UC patients was not associated with a decreased risk of subsequent PSC. The observed differences in the risk of PSC development over calendar periods are likely due to changes in PSC-diagnosis and UC-treatment.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Article Gastroenterology & Hepatology

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease

Jamie M. Horrigan, Edouard Louis, Antonino Spinelli, Simon Travis, Bjorn Moum, Jessica Salwen-Deremer, Jonas Halfvarson, Remo Panaccione, Marla C. Dubinsky, Pia Munkholm, Corey A. Siegel

Summary: This study investigated the global use and barriers to using patient-reported outcomes (PROs) in clinical practice for inflammatory bowel disease (IBD). The majority of healthcare providers use PROs in clinical practice, but there are variations in which PROs are used and how they influence management. Barriers to using PROs include lack of familiarity, integration issues, and time constraints. Education about PROs and the use of an accepted set of PROs can help overcome these barriers and achieve global harmonization.

CROHNS & COLITIS 360 (2023)

Article Gastroenterology & Hepatology

Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels

Joel Thunberg, Olle Granno, Daniel Bergemalm, Carl Eriksson, Isabella Visuri, Michael Eberhardson, Jonas Halfvarson

Summary: This study examined the agreement between a point-of-care test (POCT) by ProciseDx and the in-house enzyme-linked immunosorbent assay (ELISA) for infliximab (IFX) quantification. The results showed good agreement between the two methods, supporting the use of ProciseDx's POCT for rapid IFX quantification.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

Article Medicine, General & Internal

Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study

Jiangwei Sun, Bjorn Roelstraete, Emma Svennberg, Jonas Halfvarson, Johan Sundstrom, Anders Forss, Ola Olen, Jonas F. Ludvigsson

Summary: This study found that patients with inflammatory bowel disease (IBD) have an increased risk of developing arrhythmias. This increased risk persists even 25 years after the diagnosis of IBD.

PLOS MEDICINE (2023)

Article Medicine, General & Internal

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

Ferdinando D'Amico, Virginia Solitano, Fernando Magro, Pablo A. Olivera, Jonas Halfvarson, David Rubin, Axel Dignass, Sameer Al Awadhi, Taku Kobayashi, Natalia Sousa Freitas Queiroz, Marta Calvo, Paulo Gustavo Kotze, Subrata Ghosh, Laurent Peyrin-Biroulet, Silvio Danese

Summary: As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. A global survey was conducted to shed light on physicians' knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption. Based on the survey results, a consensus was reached on key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring, non-medical switching, and future perspectives. The consensus affirmed that biosimilars are equally effective and safe compared to originator drugs.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Gastroenterology & Hepatology

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlen, Olof Grip, Charlotte Soderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjoberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson

Summary: This study assessed the long-term outcomes of vedolizumab in treating inflammatory bowel disease. The results showed that vedolizumab had high continuation rates and was associated with improvements in clinical outcomes, health-related quality of life measures, and inflammatory markers at 2 and 3 years after treatment initiation.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred IBD BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I. R. Spencer

Summary: This study investigated a composite serum N-glycomic biomarker to predict future disease course in newly diagnosed IBD patients. The biomarker showed a predictive capacity for treatment escalation in both the discovery and replication cohorts of patients.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Eosinophilic esophagitis is associated with increased risk of later inflammatory bowel disease in a nationwide Swedish population cohort

Amiko M. Uchida, John J. Garber, Ashley Pyne, Kathryn Peterson, Bjorn Roelstraete, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson

Summary: In this nationwide cohort study, EoE was found to be associated with a 3.5-fold increased risk of later IBD diagnosis, possibly due to genetic or early environmental risk factors.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

暂无数据